Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTCOV early outpatient COVID-19 treatment trial
2020-001723-13Phase 3Completed
- Sponsor
- Groupe hospitalier Paris Saint-Joseph
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of azithromycin, lopinavir and ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Groupe hospitalier Paris Saint-Joseph. Primary endpoint: Hospital admission rate between D0 and Day 20. Started Apr 2020; status: completed.
02
Drugs
azithromycinlopinavirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001723-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001723-13.